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Involvement of PARP1 in the regulation of alternative
splicing
Elena Matveeva1, John Maiorano1, Qingyang Zhang2, Abdallah M Eteleeb3, Paolo Convertini1,4, Jing Chen1,
Vittoria Infantino4, Stefan Stamm1, Jiping Wang2, Eric C Rouchka3, Yvonne N Fondufe-Mittendorf1
1Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, USA; 2Department of Molecular
Biosciences, Northwestern University, Evanston, IL, USA; 3Department of Computer Engineering and Computer Science,
University of Louisville, Louisville, KY, USA; 4Department of Science, University of Basilicata, Potenza, Italy
Specialized chromatin structures such as nucleosomes with specific histone modifications decorate exons in eukaryotic
genomes, suggesting a functional connection between chromatin organization and the regulation of pre-mRNA splicing.
Through profiling the functional location of Poly (ADP) ribose polymerase, we observed that it is associated with the
nucleosomes at exon/intron boundaries of specific genes, suggestive of a role for this enzyme in alternative splicing. Poly
(ADP) ribose polymerase has previously been implicated in the PARylation of splicing factors as well as regulation of the
histone modification H3K4me3, a mark critical for co-transcriptional splicing. In light of these studies, we hypothesized that
interaction of the chromatin-modifying factor, Poly (ADP) ribose polymerase with nucleosomal structures at exon–intron
boundaries, might regulate pre-mRNA splicing. Using genome-wide approaches validated by gene-specific assays, we show
that depletion of PARP1 or inhibition of its PARylation activity results in changes in alternative splicing of a specific subset
of genes. Furthermore, we observed that PARP1 bound to RNA, splicing factors and chromatin, suggesting that Poly
(ADP) ribose polymerase serves as a gene regulatory hub to facilitate co-transcriptional splicing. These studies add another
function to the multi-functional protein, Poly (ADP) ribose polymerase, and provide a platform for further investigation of
this protein’s function in organizing chromatin during gene regulatory processes.
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Introduction
Alternative splicing is a cellular process that serves
to markedly increase the transcriptome and protein
biodiversity within eukaryotic cells [1]. In humans,
~ 95% of multi-exonic genes are alternatively spliced
[2, 3]. Alternative splicing events (ASEs) direct tissue-,
cell type- and developmental stage-specific gene
expression patterns in eukaryotes [4]. Alternative
splicing decisions have important roles in many cellular
processes, ranging from sex determination in fruit flies
to programmed cell death in human cells, and are
implicated in human disease [6, 5].
Alternative splicing is regulated by the binding of
trans-acting factors to their target sites on pre-mRNA.
These trans-acting factors promote or reduce the usage
of a particular splice site. Emerging data suggest that
the information present at these splice sites and the
binding of these factors in vivo may not be sufficient to
define exons or regulate alternative splicing [7]. This
has led to the ‘co-transcriptional splicing hypothesis’
[8], which suggests that splicing and transcription occur
at the same time, with local chromatin structure being
responsible for the cross-talk between transcription and
splicing. Building on this idea, several studies showed
that nucleosomes and/or specific histone modifications
affect both the association of splicing factors (SFs)
with chromatin and the efficiency of the splicing
process [8–10].
The nucleosome, the basic repeating unit of chro-
matin, consists of 147 bp of DNA wrapped around a
histone octamer; two copies each of histone H2A, H2B,
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H3 and H4. The location of nucleosomes on the
eukaryotic genome regulates cellular processes that
require DNA to transcribe, replicate, recombine and
repair DNA. Although the roles of nucleosomes
positioned at promoters have been widely studied in
transcriptional regulation, the roles of nucleosomes in
splicing regulation are less well understood [11, 12].
The positioning of nucleosomes at exons [13, 14] is
dependent on several factors including the intrinsic
DNA sequence [15, 16], DNA methylation levels
[17, 18] and histone modifications [19]. Indeed,
nucleosomes regulate RNA polymerase elongation
kinetics, thus aiding in the recognition of weak splice
sites [7, 17]. These nucleosomes typically associate with
DNA that has a high GC content, high DNA methy-
lation pattern and specific histone post-translational
modifications (PTMs), which are all factors that
influence nucleosome stability [7, 17, 20–23]. In
support of a splicing regulatory role of histone PTMs,
data in yeast show elevated transcription levels
are associated with reduced histone occupancy. In
addition, the transcription-associated H3K36me3
modification is reduced at alternatively spliced exons
compared with constitutive exons [22, 24].
As alternative splicing appears to occur co-
transcriptionally in vivo, we hypothesize that factors
affecting chromatin stability and dynamics regulate
alternative splicing. Although the roles of histone
PTMs and DNA methylation in co-transcriptional
splicing have been extensively studied, the role of
other chromatin modulators in this process is less
studied. One potential modulator is poly (ADP)-ribose
polymerase 1 (PARP1), which is known to remodel
chromatin through PARylation (addition of poly
(ADP) ribose moieties) of histones to regulate
transcription. Through profiling of PARP1 chromatin-
binding sites, we found sharp occupancy peaks for
PARP1 at internal intron/exon boundaries, suggesting
a role in pre-mRNA splicing. Our studies suggest that
PARP1 acts as a structural chromatin entity and an
adapter molecule bridging chromatin and RNA, and as
a recruiter of SFs. These studies comprise the first
comprehensive genome-wide determination of PARP1
in mediating gene regulation at the splicing level.
Results
We assessed the genomic distribution of PARP1 in
S2Drosophila cells by nucleosome-chromatin immuno-
precipitation using PARP1 antibody followed by deep
sequencing (nuc-ChIP-seq) (Supplementary Figure S1).
The Drosophila system provides a convenient model
to test the effect of PARP1 on gene regulation as
Drosophila contains only one PARP1 gene and a
tankyrase, compared with at least 18 different PARP
genes in humans [25, 26].
PARP1 preferentially binds active promoters
Previous studies using ChIP-chip experiments as
well our recent nuc-ChIP-seq show that PARP1 binds
Figure 1 PARP1 is enriched around the promoters of active genes and depleted at the ends of genes. Dyad density plot of
PARP1-bound nucleosomes and total nucleosomes in S2 cells around (a) transcription start sites (TSSs) and (b) transcription
termination ends (TTEs). To control for the difference in the total number of tags, dyad density scores are normalized by the
average density over the genome.
PARP1's role in cotranscriptional splicing
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to active promoter regions in human cells [27, 28].
We sought to determine whether this is true in the
Drosophila genome, where the presence of a single gene
permits a higher resolution nuc-ChIP-seq analysis.
Using this analysis, we examined the distribution of
PARP1-nucleosome reads within 2 kb upstream and
downstream of annotated transcription start sites
(TSSs), as described in the Materials and Methods
section. We observed that PARP1 associates with the
+1 and +2 nucleosomes of active promoters (Figure 1a)
and not with the nucleosomes at the transcription
termination ends (TTEs, Figure 1b). These data are
consistent with previous lower resolution studies that
show PARP1 enriched at +1 and +2 nucleosomes
of heat-shock genes [29, 30] as well as our recent
high-resolution analyses of PARP1 binding in human
cells [28]. Based on this observation, we further
quantified the relationship between gene expression
and PARP1 interaction with promoters, by calculating
the Pearson correlation between gene expression
and PARP1-nuc-ChIP-seq read depth across − 50 to
+500 bp surrounding annotated promoter regions.
PARP1 association correlates positively with gene
expression (Pearson correlation R= 0.427; P= 2.2e-16).
Performing the same analyses at the ends of genes
showed a very weak/no correlation with gene
expression levels (R= 0.0196; P= 0.025).
PARP1 associates with exonic nucleosomes
While profiling PARP1 genomic location, we
observed PARP1-nucleosome signals at exon–intron
boundaries. To test whether the binding of PARP1 in
coding regions was related to the chromatin archi-
tecture around exon/intron junctions in Drosophila,
a fine chromatin structure map of PARP1 occupancy
across the coding regions of active genes and silent
genes was generated (Figure 2). These analyses showed
that PARP1 associated with nucleosomes within
exons, irrespective of the transcriptional status of the
genes (Pearson correlation R= 0.325; P= 1.5e-16)
(Figure 2a–d). We next addressed whether the sharp
peak of PARP1-bound nucleosomes observed at the
exon/intron and intron/exon boundaries was a special
feature of PARP1 chromatin structure at these regions.
We compared the profiles of total nucleosome
occupancy with those of PARP1-bound nucleosomes
at the intron–exon boundaries (Figure 2a and c)
and exon–intron boundaries (Figure 2b and d). We
observed a difference in both profiles: higher peak in
the PARP1-bound nucleosome profile with a deeper
valley past these peaks than with total nucleosome
profiles. From these analyses, we concluded the
observed peaks in the PARP1-nuc-seq data are not
solely the consequence of increased nucleosome
occupancy in this region, but an enrichment of
PARP1-bound nucleosomes at these regions.
To differentiate the observed effect of PARP1 at
TSSs with those at the internal exons, we asked if there
was a difference between PARP1-bound nucleosomes
at the first exon/intron boundaries compared with
PARP1-bound nucleosomes at internal exon/intron
boundaries. To address this question, PARP1-bound
nucleosome footprints centered on the 5’ sites of all
exons were constructed. This analysis showed low
levels of PARP1-bound nucleosomes at the ends of first
exons (excluding ± 250 bp surrounding annotated
TSSs) (Figure 3a), whereas PARP1-bound nucleo-
somes were abundantly positioned at the start of
internal exons (Figure 3b). To ensure that nuc-ChIP –
seq technique did indeed pull down PARP1 targets,
chromatin was digested with different amounts of
MNase, resulting in varying lengths of chromatin
(Supplementary Figure S2A). ChIP-qPCR (quantita-
tive real-time polymerase chain reaction) was
performed to validate PARP1 binding at target and
non-target genes (Supplementary Figure S2B–D). The
results show that PARP1-nucleosome binding is
specific validating the nuc-ChIP-seq results (PARP1-
nuc-ChIP profiles are shown in Supplementary
Figure S2E). Analyses of gene ontology by the Data-
base for Annotation, Visualization and Integrated
Discovery (DAVID) Bioinformatics Resources (ver-
sion 6.7) [31] of the genes bound at the internal exon/
intron boundaries by PARP1 showed that these genes
were involved in several important gene regulatory
processes (Supplementary Figure S2F and Supplemen-
tary Table S1).
PARP1 associates with GC-rich nucleosomes and with
active histone modifications
Previous work demonstrates that the preference for
nucleosome positioning over exons is influenced by
nucleotide sequence composition. Across eukaryotes,
exon sequences tend to have elevated GC content
compared with flanking introns [7, 17, 20, 32].
As higher GC content confers stability to exonic
nucleosomes [15, 33], we sought to determine whether
PARP1-bound nucleosomes are particularly GC-rich.
We found that as the GC percentile increases, more
PARP1 reads (compared with total nucleosomes) were
mapped, indicating that PARP1-associated nucleo-
somes at the internal exon/intron boundaries are, on
average, GC-rich (Figure 3c). GC-rich nucleosomes
have been suggested to bind to weak splice sites,
Elena Matveeva et al.
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slowing down the rate of RNAPII elongation [20, 34],
which might promote co-transcriptional splicing.
We next investigated the association of PARP1
with specific histone modifications. We downloaded
a large set of histone modification data on S2
Drosophila cell line from the modENCODE project
[35]. Analyses of our PARP1-nuc-ChIP-seq results
(PARP1 binding) showed an overlap of PARP1-
binding with several active histone PTMs ChIP-seq
data (Figure 3d) such as H3K4me3, H3K36me3,
H4K16ac but not with the repressive histone PTM
H3K27me3 nor H1.
Global ASEs mediated by PARP1 and its PARylation
activity
As PARP1 is associated with nucleosomes at exon
boundaries, we hypothesized that PARP1-associated
chromatin structure might function in alternative
splicing. To test the functionality of PARP1 in
alternative splicing, we used small interfering (siRNA)
to knockdown PARP1 in S2 Drosophila cells (com-
pared with cells treated with LacZ control siRNA).
PARP1-knockdown efficiency was determined at
both protein and mRNA levels (Supplementary
Figure S3A and B). As previous studies have shown
that PARylation of proteins within the spliceosomal
complex is important for their activity [36, 37], we also
asked whether the observed effects on alternative
splicing were dependent on PARP1’s PARylation
activity by inhibiting PARylation using PJ-34 [29, 38]
(Supplementary Figure S3C).
To address the global impact of PARP1 on
alternative splicing, we isolated total RNA in two
biological replicates from control (non-treated),
PARP1 siRNA- and PJ-34-treated cells. Sequencing of
these RNAs on an Illumina HiSeq 2500 yielded 456
million 100-bp paired-end RNA-seq reads. First,
we aligned reads to the entire gene body of PARP1
and confirmed a reduction in PARP1 expression of
~ 30% (Po10− 3). This result is consistent with the
quantitative reverse-transcription PCR (qRT-PCR)
data (Supplementary Figure S3B), and confirms
PARP1 depletion after PARP1 siRNA treatment
(Supplementary Table S2). We next used these RNA-
seq data sets (control, PARP1 KD and PARylation
inhibited) to assess whether these treatments resulted in
changes in (i) gene expression and (ii) alternative
splicing.
Figure 2 PARP1 demarcates exons and is enriched at intron/exon and exon/intron boundaries irrespective of the transcriptional
state of the genes. For this calculation, intron-containing genes were used and curves were normalized by genome-wide average.
Dyad density of PARP1 nucleosomes at (a) start of exons (intron/exon) and (b) end of exons (exon/intron) of active genes,
respectively. Dyad density of PARP1 nucleosomes at (c) start of exons (intron/exon) and (d) end of exons (exon/intron) of inactive
or silent genes, respectively. To control for the effect of nucleosomes, dyad density scores are normalized by the average density
over the genome (see Supplementary Figure S1).
PARP1's role in cotranscriptional splicing
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Figure 3 Characteristic features of PARP1-bound nucleosomes. (a) PARP1-bound nucleosomes (red curve) are not enriched at
first exons boundaries but are (b) highly enriched at internal exons (tag densities were measured at ± 1000 bp), even if the effect
of total nucleosome (green curve) is subtracted. For this calculation only intron-containing genes were used. (c) PARP1
associates with GC-rich nucleosomes. Plot shows PARP1-bound nucleosome density relative to total nucleosome density as a
function of GC content. The black curve is the fitted smoothing line by loess method (local regression) using locally weighted
polynomial regression analyses. (d) Heatmap showing that PARP1 binding overlaps with chromatin regions occupied by specific
histone modifications. Pearson correlations of PARP1 and the following epigenetic marks (all with P-valueso1010).
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Gene expression patterns mediated by PARP1 and
PARylation
Using the Tuxedo protocol for RNA-seq analysis
[39], PARP1 depletion resulted in ~ 849 differentially
expressed genes (DEGs) (P⩽ 0.05), of which 210 were
upregulated (Supplementary Table S2C) and 639 were
downregulated (Supplementary Table S2D). We used
categoryCompare [40] to determine the function of
these DEGs (Supplementary Figure S4A). Genes
upregulated after PARP1 knockdown are mainly
involved in nucleotide metabolism, ATP synthesis
and spindle (centromere) formation, whereas those
downregulated genes are involved in differentiation,
growth, migration and development (Supplementary
Table S2E). Inhibition of PARylation affected the
expression of 1281 genes; 974 of these were upregulated
(Supplementary Table S2A) and 307 were down-
regulated (Supplementary Table S2B) (P⩽ 0.05).
Interestingly, the top category of genes upregulated
after PARylation inhibition are involved in the
spliceosome and in RNA polymerase-processing
pathways, whereas downregulated genes are involved
in neuronal differentiation, cell death and immune
response (Supplementary Table S2F). Comparison of
the DEGs mediated by PARP1 knockdown and
PARylation inhibition reveals 182 genes common to
both (Supplementary Figure S4A and B) with no
common directionality in the gene expression profiles.
Changes in gene expression were validated using
qRT-PCR, with 8 out of 10 genes (90%) in accordance
with RNA-seq data (Supplementary Figure S4C).
Alternative splicing patterns mediated by PARP1 and
PARylation
We asked next if PARP1 or PARylation controls the
expression patterns of alternative transcript isoforms at
the transcriptome level. MATS (multivariate analysis
of transcript splicing) [41] and MISO (mixture of iso-
forms) [42] were used to estimate expression levels
of different mRNA isoforms (Supplementary Figure
S5A). Both methods use a Bayesian approach to cal-
culate the ASEs between two samples; however, MATS
measures ASEs, whereas MISO determines both
isoform and event-inclusion level [43]. We used both
methods to identify targets for which PARP1 or
PARylation modulates the following pre-mRNA pro-
cessing event subclasses: (i) mutually exclusive exons,
(ii) cassette exons (skipped exons (SEs) according to
MATs analyses), (iii) alternative 3′ and 5′ splice sites
and (iv) retained introns (Supplementary Figure S5A).
Some events were commonly detected only by MISO
(Supplementary Table S3), whereas others were
detected by both methods (Figure 4a and d and
Supplementary Figure S5A; Supplementary Table S4),
indicating the validity of these events. MISO (ΔΨ of 0.2
and Bayes factor ⩾ 10) detected a total of 1540 events
(4.5% of total MISO-detectable ASEs) regulated by
PARP1 independent of its catalytic activity and 745
events (2% of total MISO-detectable ASEs) regulated
through the PARylation activity of PARP1. Likewise,
MATS at Po0.005, identified 135 events (3% of total
MATS-detectable ASEs) as regulated by PARP1 and
290 events (4% of MATS-detectable ASEs) as regu-
lated through the PARylation activity of PARP1
(Figure 4a). Examples of ASEs determined by MISO
are illustrated using Sashimi plots (Figure 4b and
Supplementary Figure S5B). Overall, these results
show that irrespective of the model used (MISO or
MATS), PARP1 and PARylation have a broad role in
regulating mRNA processing events in Drosophila
S2 cells.
At last, we again performed categoryCompare
analysis [40] to examine whether transcripts modified
by PARP1/PARylation were enriched for particular
functional categories (Figure 4c). The top category
found to be affected by PARP1 depletion and inhibi-
tion of the PARylation activity of PARP1 were genes
involved in RNA splicing, with many core and reg-
ulatory components (including members of the SR and
hnRNP families). We conclude from these results that
PARP1 and PARylation preferentially affect tran-
scripts encoding protein products involved in RNA
and protein-processing pathways (Figure 4c and
Supplementary Table S3). Though, PARP1 depletion
and PARylation inhibition affected the expression of
several genes (Supplementary Figure S4A), 87% of the
genes regulated by PARP1 at the splicing level were
not affected in their level of mRNA expression
(Supplementary Table S2). Of note, depletion of
PARP1 did not substantially affect the expression
of SFs (Supplementary Table S2C and D), though
PARylation did affect the expression of SFs
(Supplementary Table S2A and B). This suggested that
there is a possible difference in the molecular mech-
anisms affected by PARP1 from its enzymatic activity.
We also analyzed the overlap between PARP1/
PARylation RNA-seq data and PARP1-ChIP-seq data
to determine the PARP1-bound genes that undergo
PARP1/PARylation-mediated ASE changes. We
observed an ~ 23–33% commonality, respectively, in
these data sets (Supplementary Table S4). Given the
technical differences in protocols and the inherent loss
of information in threshold and significance threshold
calls, this number of genes is likely a conservative
PARP1's role in cotranscriptional splicing
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estimate. Next, we identified genes affected at both
their expression and splicing levels by PARP1 siRNA
compared with inhibition of PARylation. Surprisingly,
although these analyses revealed some commonalities,
the profiles were largely different (Figure 4d). For
instance, PARP1 and PARylation regulated only
four genes in common at both gene expression and
splicing levels: CG40178, CG40191, ASCL (Acyl-CoA
synthetase long-chain) and PARP1 itself.
At the gene expression level, genes shared by the
PARP1 and PARylation function in several pathways,
including neuron differentiation, cell death and
immune response. Intriguingly, at the splicing level,
PARP1 and PARylation commonly regulated 72 genes
as determined by MATS, of which many are involved
in splicing (Figure 4a and c). These results are
consistent with two possible modes of PARP1 function
in alternative splicing that are not mutually exclusive:
(1) as a structural chromatin protein, PARP1 can
directly affect alternative splicing through association
with chromatin structures that affect RNA polymerase
elongation and/or act as an adapter for RNA and SF
binding; and (2) through PARylation of SFs PARP1
can indirectly affect splicing by regulating the activity/
expression of spliceosomal proteins (Figure 4).
Validation of ASEs regulated by PARP1 and
PARylation
We used semi-qRT-PCR to validate the changes in
alternative splicing observed in RNA-seq analyses after
PARP1 KD and PARylation inhibition. For these
analyses, we chose representative genes based on the
ChIP-seq data showing PARP1-binding at internal
exon–intron boundaries of target genes as well as
RNA-seq experiments, showing PARP1-/PARylation-
mediated ASEs at these genes. These splicing events fall
Figure 4Global gene regulatory events mediated by PARP1 and its PARylation activity. (a) Four-way Venn diagram showing the
different types of ASEs that are detected by either MATS or MISO detected by both methods. (b) Sashimi plots showing example
of ASEs mediated by PARP1 and PARylation. RNA-seq read densities supporting ASEs and the estimated confidence levels are
shown in the figure. (c) Visualization of the Gene Ontology Biological Process (BP) categories of PARP1 and PARylation-
mediated ASEs. Circles are shaded based on types of ASEs as indicated on the legend. (d) Four-way Venn diagram summarizes
the number of shared proteins in each combination of the four groups. Yellow and green: PARP1-mediated DEGs and ASEs,
respectively; purple and red: PARylation-mediated DEGs and ASEs, respectively (Po0.01, by Student’s t-test). Numbers
depicted in the intersections between circles represent the numbers of genes that are commonly regulated in two, three, or four
conditions.
Elena Matveeva et al.
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into several classes: (i) alternative 5′ splice site (SS)
usage, (ii) alternative 3′ SS usage and (iii) exon
skipping. We confirmed that knockdown of PARP1
resulted in changes in ASEs at these genes (Figure 5,
lane 5: RNAi-1). A second siRNA targeting a distinct
sequence within the PARP1 gene, KD2, was used to
corroborate that the observed changes in alternative
splicing was due to the knockdown of PARP1 and not
specific to the sequence of the PARP1 siRNA
(Figure 5, lane 6: RNAi-2).
We also tested and validated the effect of the
PARylation activity of PARP1 in S2 cells on alter-
native splicing of these genes (Figure 5, Lane 3). We
further confirmed the effect of PARylation on alter-
native splicing in a fly model, PARPC03256 that expresses
a short isoform of the PARP1 protein lacking the first
zinc finger, with reduced PARylation activity [44].
Indeed, comparing splice isoforms between wt and
PARPC03256 mutant flies showed changes in ASEs
(Figure 5, lane 1 and 2). The observed splicing
patterns were further validated quantitatively using
quantitative real-time PCR at specific alternative exons
(Supplementary Figure S6A and B). In all experimental
conditions tested (PARP knockdown, PJ34-treated and
PARPC03256) compared with wild-type cells or flies, no
changes in the expression at constitutive exons were
observed (Figure 5h).
PARP1 is recruited to chromatin and pre-mRNA
Based on the findings above, we considered
three possible recruitment mechanisms for PARP1 in
splicing:
First, we asked whether the splicing effects we
observed after PARP1 knockdown or PARylation
inhibition were due to changes in nucleosome
occupancy over these exons. For this, we carried out
ChIP-qPCR analyses to measure nucleosome and
PARP1 occupancy at the exons of selected genes.
Knockdown of PARP1 (PARP1 KD) resulted in
depletion of PARP1 occupancy at these experimental
exons – Stau (Figure 6a); Fl(2)d (Figure 6b); Capt
(Figure 6c) with no measurable change in nucleosome
density, as measured by histone H3 occupancy
(Figure 6, Lane 2). Contrary to PARP1 KD,
Figure 5 PARP1 regulates alternative splicing. (a–g) Measurements of ASEs at alternative exons. (h) Measured gene expression
of constitutive exons. Representative gel images of the effect of PARP1 and PARylation on ASEs. Total RNA from wt and
ParpC03256 flies were tested for changes in ASEs (lanes 1 and 2). S2 cells treated with PJ34 (lane 3), S2 cells treated with (i) LacZ
non-targeting siRNA (lane 4), (ii) PARP1 siRNA1, (iii) PARP1 siRNA2 (KD1 and KD2, lanes 5 and 6, respectively). Bar charts
represent the alternative arbitrary units from qRT-PCR measured as a rate of alternative exon included over the sum of all the
alternative exons calculated from the mean intensities (n⩾ 3 biological replicates, ±S.D.; Po0.05 with Student’s t-test; see
Supplementary Figures S2 and 3). Black and white boxes represent constitutive exons 5′ and 3′ to the alternative exons (gray
boxes), respectively. Red arrows depict locations of primers.
PARP1's role in cotranscriptional splicing
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PARylation inhibition had no effect on nucleosome
density (H3 occupancy) or PARP1 occupancy
(Figure 6a–c, Lane 2 and 4), corroborating previous
results [45].
Second, we asked if at these exons, PARP1
associates with specific histone modifications that have
been implicated in splicing. In these studies, we focused
on H3K4me3 for several reasons: (1) H3K4me3 is
proposed to facilitate SF loading [10], (2) we show both
in human cells [46, 47] and S2 Drosophila cells
(Figure 3d) that PARP1 binding correlates positively
with H3K4me3 presence (in S2 Drosophila cells
with a Pearson correlation R= 0.6215; Po10− 10).
ChIP-qPCR analyses confirmed the co-presence of
H3K4me3 and PARP1 at the nucleosomes of these
PARP1-target exons (Figure 6a–c, Lane 3 and 4). In
the absence of PARP1 (PARP KD), a concomitant
reduction (~60%) of H3K4me3 occupancy at these
target exons was observed (Figure 6a–c), confirming
previous studies of a role of PARP1 in H3K4me3
deposition [46]. We therefore hypothesized that
this reduction is specific for PARP1 knockdown as
knockdown of Histone H1, a protein that competes for
nucleosomal binding with PARP1 [27], had no sig-
nificant effect on H3K4me3 or PARP1 occupancies at
these exonic sites (Figure 6, Lane 3 and 4). However, at
Figure 6 Co-occupancy of PARP1 and H3K4me3 at PARP1-target exons. S2 cells were transfected with siRNA targeting lacZ
(NT) and PARP1 (PARP1 KD). ChIP-qPCR analysis of PARP1, nucleosome density (as measured by H3) and H3K4me3
occupancies at PARP1-target exons in (a) Stau, (b) Fl(2)d and (c) Capt1 genes were analyzed in NT, PARP1 KD and
PJ34-treated S2 cells. As proof of the specificity of the observed effect, these same factors were measured in Histone H1
Knockdown cells (H1 KD). Representative inverted agarose gel images of qPCR products stained with Gelstar are shown
(far left). Bar graphs show ChIP-qPCR (quantitative real-time PCR) analyses normalized to IgG control of the measured
occupancies. Antibodies used are indicated above each graph; results are represented as mean plus s.e.m. (n⩾ 3; Student's
t-test, Po0.05). Primers that target the alternative exons as in Supplementary Figure S5B were used in ChIP PARP1, H3K4me4
co-occupancy assays.
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other PARP1-target regions, no H3K4me3 was found
(Supplementary Figure S6C), implying that other
factors or histone modifications might also be
important for PARP1-nucleosome association. On the
other hand, compared with PARP1 KD, no reduction
in H3K4me3 occupancy (Figure 6, Lane 3) was
observed in PJ34-treated cells as previously reported
[46]. We believe the difference could be due to length of
PJ34 treatment and/or cell type (S2 cells with one
PARP1 and MCF7 cells with several PARP1s).
Taken together, these results support our findings of
the differential splicing outcomes in PARP1 KD and
PARylation-inhibited cells. And, as with the case of
PARP1’s function in transcription, the physical
presence of PARP1 is critical in some molecular
pathways, possibly involving the chromatin structure,
whereas PARylation is important in others [27, 44, 48].
Third, we hypothesized that PARP1 might act as an
adapter bringing RNA to specific regions of chromatin.
To test this hypothesis, we first sought to determine
whether PARP1 binds RNA in vivo. To this
end, PAR-CLIP (photoactivatable cross-linking and
immunoprecipitation) protocol [49] (Figure 7a) was
used and PARP1-associated RNAs were immunopre-
cipitated with a PARP1 antibody (Figure 7a and b).
As spliceosome dynamics and composition are very
similar between Drosophila and humans [50], and most
known human-SFs have orthologues in flies [51],
experiments were performed in both S2 and HeLa cells.
Complexes representing the expected molecular weight
of a single molecule of PARP1 bound to its target
RNAs were observed in both cell types. This band was
eliminated in stringent RNase A treatment as well
as in PARP1 KD cells (Figure 7b and Supplementary
Figure 7 Identification of PARP1 interactome in vivo. PARP1 is covalently cross-linked to nascent RNAs using 365 nM iUV light
and 4-thiouridine. PARP1-bound nascent RNAs are immunoprecipitated using PARP1 antibody and then purified under stringent
conditions. (a) PAR-CLIP procedure. (b) Radiolabeled PARP1-bound RNAs are blotted onto nitrocellulose, released by
proteinase K and analyzed on a phosphoimager. The same blot was probed with anti-PARP1 antibody confirming PARP1-RNA
binding. Knockdown of PARP1 or stringent RNase treatment of immunoprecipitated samples eliminated the PARP1-RNA band.
Furthermore, protein samples resulting from PAR-CLIP experiments were split into three aliquots (i) no further treatment; (ii)
stringent DNase1 treatment; (iii) stringent RNase A. These samples were subjected to mass spectrometry (Supplementary Table
S5). (c) Proteins released from stringent RNase A and DNase1 digests were analyzed on a coomassie-stained gel and also
probed with anti-H3 antibody to show depletion of histones.
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Figure S7A). Our data from three independent
experiments show direct in vivo binding of PARP1 to
RNA, supporting previous studies that showed or
postulated the binding of PARP1 to RNA and RNA
binding proteins [52–54]. In effect, the binding of
PARP1 to mRNA at some target exons (Figure 5) was
validated after PAR-CLIP in both cell types using
RT-PCR (Supplementary Figure S7B). Our inability to
validate CAPT/CAP mRNA binding could be due to
the differences in conditions used in the different
methods (nuc-ChIP-seq versus PAR-CLIP-qRT-PCR).
As PARP1 is a known chromatin-binding protein,
we tested the possibility that PARP1 binds both RNA
and chromatin at the same time. Following the PAR-
CLIP experiment and after PARP-IP − although the
PARP1:RNA complexes were still on beads − samples
were subjected to polyacrylamide gel electrophoresis
(PAGE) analyses. Gel pieces were excised, trypsin-
digested and used for tandem mass spectrometry
analyses to determine the protein components. We
filtered and retained only proteins with a stringent
mascot level of 423, with more than four unique
peptides and present in four independent experiments.
We observed the presence of histones, other chromatin
proteins and proteins involved in pre-mRNA
regulation (Figure 7c and Supplementary Table S5).
Based on these results, we believe that PARP1 is in a
complex with chromatin, RNA and SFs. Remarkably,
the stringent RNase A or DNase I digest of PAR-CLIP
samples resulted in the a significant number of RNA or
DNA (chromatin) proteins, respectively (Figure 7 and
Supplementary Table S5).
Fourth, PARylation has been proposed to assist in
the opening of chromatin structure and to increase
access of factors to DNA [29, 30, 55]. Given that
PARP1 binds chromatin and mRNA (Figure 7) and
given that PARylation activates SFs [37, 44, 56] we
speculated that PARP1 might be recruiting SFs. For
this purpose, we analyzed the association of PARP1
and the SF 3B subunit 1 (SF3B1), a component of the
U2 snRNPs. Owing to the availability of ChIP-grade
antibodies, these experiments were carried out in
human HeLa cells. NChIP experiments using anti-
bodies specific for SF3B1 were performed and probed
for the presence of PARP1. Most SF3B1-bound
nucleosomes also contained bound PARP1 as
exemplified with SF3B1-ChIP (Figure 8a, Lane 3).
Furthermore, in H3-pulldowns, we observed the pre-
sence of some SF3B1, implying that SF3B1 binds only
a small subset of all nucleosomes (Figure 8a, Lane 4).
PARP1, on the other hand, binds to more nucleo-
somes, possibly because of its role in other chromatin
gene regulatory programs, not necessarily linked to
SF3B1. To provide additional evidence for a physical
association between PARP1 and SFs, we fractionated
HeLa nuclear extracts on a 10− 30% glycerol gradient.
We observed PARP1 co-sedimenting with SF3B1
(fractions 6–14 in Supplementary Figure S8), arguing
for a stable association between PARP1 and SF3B1.
These results are in line with previous studies showing
spliceosomal complexes as part of PARP1 interactome
[57] and vice versa: PARP1 as one of the interacting
proteins in the spliceosomal complex [58]. As
PARylation is known to affect protein complex
stability [59, 60], we asked whether this PARP1-SF3B1
association requires PARylation. Though PJ34
treatment resulted in a significant decrease in global
PARylation levels (Supplementary Figure S3C),
this treatment did not abrogate PARP1-SF3B1-
nucleosome association as measured by ChIP
(Figure 8b). Knockdown of PARP1 resulted in less
SF3B1 association with nucleosomes, implicating
PARP1 in stabilizing the SF3B1-nucleosome complex
(Figure 8b). Taken together, our results support the
idea that a fraction of PARP1 is in a complex with
spliceosomal components, possibly recruiting them to
relevant sites important for splicing regulation.
Discussion
The findings presented here reveal a functional role
for PARP1 in the regulation of pre-mRNA splicing.
In particular, we have shown that PARP1 binds to
nucleosomes at exon/intron boundaries corresponding
to specific splice sites. In addition, we demonstrate that
knockdown of PARP1 or inhibition of its PARylation
activity, leads to changes in specific alternative splicing
patterns. Moreover, PARP1 and its PARylation activity
have distinct effects on splicing with nucleosomal
PARP1 causing direct changes in ASEs, whereas
PARylation inhibition resulted in changes in gene
expression of SFs, implying an indirect effect on splicing.
Our findings thus reveal an important role for PARP1 in
regulating alternative splicing, at both the gene-specific
and global level. Importantly, we find that in addition to
its well-established association with chromatin, PARP1
displays in vivo RNA binding and binds to SF3B1,
a member of the U2 spliceosomal complex.
Our studies show also that the effects of PARP1 or
PARylation inhibition are quite distinct from each
other, with no specific direction in splicing modulation
(exon inclusion or exon exclusion). Surprisingly,
our analyses showed little overlap between ASEs
modulated after PARP1 knockdown and PARylation
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inhibition. We hypothesize that these differences are
due to several possible reasons:
First, PARP1 knockdown results in a general
reduction in PARP1 occupancy over PARP1-target
exons, whereas PARylation inhibition does not change
PARP1 occupancy (Figure 6). In fact, we observed a
slight reproducible increase in PARP1 occupancy after
PARylation inhibition, though more studies will be
needed to validate this finding. However, these results
are in line with previous studies showing that extensive
PARylation of PARP1 inhibits its nucleosome binding
[61–63]. On the other hand, it is plausible that lack of
PARylation results in less-PARP1 degradation, as
PARylation negatively regulates certain proteins by
dissociating protein complexes or by promoting their
ubiquitination and their proteasomal degradation
[59, 60].
Second, our studies show that with PARP1
knockdown, PARP1 is absent at these exons with a
concomitant decrease in H3K4me3, whereas with
PARylation inhibition, PARP1 and H3K4me3 are
present. If PARP1 were to function by regulating the
deposition of H3K4me3 [46], a histone modification
implicated in splicing, there would be a difference
between the splicing outcomes between PARP1 KD
and PARylation inhibition.
Third, PARylation inhibition had no effect on
PARP1-SF3B1-nucleosome binding (Supplementary
Figure S8A). A similar situation has been shown
during transcription, where PARP1 is essential for
recruiting the transcription machinery, such as the
mediator complex or co-regulators (for example,
p300), and its catalytic activity is not required in these
processes [64, 65].
Figure 8 PARP1 regulation of co-transcriptional splicing. (a) PARP1 and SF3B1 bind to the same nucleosomes. SF3B1
(U2 snRNP) ChIP shows that most SF3B1-bound nucleosomes (SF3B-IP) also bind PARP1. However, PARP1 binds other
nucleosomes as indicated by H3 ChIP. Knockdown of PARP1 impaired the association of SF3B1 to nucleosomes, whereas
inhibition of PARylation had no significant effect. (b) ChIP experiments showing co-occupancy of PARP1 and SF3B1 in HeLa
cells. Knockdown of PARP1 resulted in reduction of SF3B1-nucleosome association, whereas PARylation inhibition (PJ34
treatment had no such effect). The results (bar graph) are represented as mean plus s.e.m. (n⩾ 3; Student's t-test, *Po0.05).
(c) Model of PARP1 in mediating co-transcriptional splicing. PARP1 binds to specific nucleosomes at exons (specified by specific
histone PTMs, for example, H3K4me3) and also binds to the nascent pre-mRNA and recruits SF3B1 a U2 component. U2 binds
to the branch-point recognized by the splicing machinery, allowing PARP1 to influence exon recognition. RNA polymerase II
generating the nascent pre-mRNA is shown on the right.
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Our studies showing differential effects on ASEs
mediated during PARP1 KD and PARylation inhibi-
tion is thought to be a consequence of the absence of
PARP in PARP1 knockdown, whereas in PARylation
inhibition, PARP1 is still present and can effect
changes in ASE. This finding supports distinct roles of
PARP1 and PARylation in splicing regulation; a direct
effect by PARP1 produced by the presence of the
PARP1 protein and an indirect effect produced by
PARylation. Indeed PARylation has been shown to
have key roles in transcription regulation in some
contexts [44, 46, 66], whereas being dispensable in
others [67, 68]. A recent study by Muthurajan et al.
[48]. shows that PAR on PARP1 switches PARP1 from
a chromatin architectural protein to a histone chaper-
one and nucleosome assembly factor, demonstrating
differential functional outcomes between PARP1 as a
protein per se and PARP1’s catalytic activity. In
addition, though the Drosophila genome encodes
only one PARP1 protein, it also encodes a tankyrase
(PARP5 in humans) with a PARylation activity,
therefore the differences in PARP1 knockdown effect
versus PARylation inhibition on splicing, could also be
masked by functional redundancy.
Finally, the co-presence of PARP1 and H3K4me3,
may point to the specificity of PARP1 binding.
However, positive correlations genome-wide of
PARP1-chromatin-binding with chromatin regions
containing other histone modifications such as
H3K36me3 and H2Av (Figure 2c) that have been
implicated in splicing (reviewed in ref. 69) were also
observed. It is therefore possible that other histone
modifications might also be important in targeting
PARP1 to specific regions of the genome. It is therefore
possible that PARP1 recognizes specific histone
modifications to regulate alternative splicing decisions.
Indeed, it has been hypothesized that adapter proteins
recognize specific histone modifications and recruit SFs
close to chromatin and thus aid in co-transcriptional
splicing. The activities of adapter proteins range from
activation and repression of transcription, chromatin
remodeling, or splicing efficiency as well as other
activities [70]. It has been suggested that H3K4me3
serves to facilitate the competency of premRNA
maturation through the bridging of spliceosomal
components [10]. PARP1, therefore, might act as an
adapter associating with H3K4me3 at exons and aiding
to bridge SFs to functional sites on chromatin.
We propose the following model (Figure 8c):
PARP1 binds to nucleosomes containing H3K4me3 at
exons as well as sites on nascent RNA, and through its
association with U2 snRNP regulates usage of
alternative exons. In this scenario, PARP1 not only
acts as an adapter, ensuring that nascent pre-mRNAs
are held close to chromatin [71], but also marks the
exons both on chromatin and the nascent pre-mRNAs.
Our data (Figure 1) showing PARP1 presence at exons
and our ability to amplify some of the PARP1-bound
exons from PARP1-bound RNAs (Supplementary
Figure S6B) support this idea. Furthermore, PARP1
bound at these exonic sites on pre-mRNA is then able
to recruit SFs to these regions. Several observations
support this possibility. First, our CLIP-mass spectro-
metry data show that PARP1 is in a complex with
chromatin, and associate with RNA and SFs (Figures 7
and 8a and b and Supplementary Figure S7A).
Also PARP1 knockdown results in impaired SF3B1-
nucleosomal recruitment (Figure 8b). Our studies
suggest that PARP1 adds another layer of complexity
to chromatin modulation in co-transcriptional splicing,
and support a model in which PARP1-containing
complexes regulate gene expression at both transcrip-
tion initiation and pre-mRNA-splicing levels. Future
studies are important to decipher the mechanism of
PARP1 in RNA biogenesis.
Materials and Methods
S2 and HeLa cell culture
Drosophila melanogaster S2-DRSC cells (obtained from the
Drosophila Genomics Resource Center) were cultured in
Schneider’s Drosophila medium (Life Technologies, Grand
Island, NY, USA) supplemented with 10% fetal calf serum
(Hyclone, Logan, UT, USA). HeLa cells were obtained from the
American Type Culture Collection (Rockville, MD, USA) and
cultured Dulbecco’s modified Eagle’s medium containing 1 mM
sodium pyruvate, 0.1 mM non-essential amino acid, 10% fetal calf
serum, 100 U/ml penicillin and 100 μg/ml streptomycin at 37 °C
in a humidified environment containing 5% CO2 and 95% air.
Drosophila strains
All Drosophila strains were kept on standard media at 25 °C.
wild-type Oregon R and PARPC03256 mutant flies [44] were
obtained from Professor Tulin. All experiments used cells were
experimental samples and controls were growth time and
cell-density matched.
ChIP of PARP1-bound nucleosomes
Chromatin fixation and immunoprecipitation were per-
formed essentially as described by [72]. In brief, 1 × 107 cells were
resuspended in PBS and fixed with 1% formaldehyde for 10 min.
Next, cells were washed and pelled cells were resuspended in
lysis buffer (1% SDS, 10 mM EDTA, protease inhibitors, 50 mM
Tris–HCl, (pH 8)) for 5 min on ice. Resulting nuclei were
pelleted and washed with MNase buffer (10 mM Tris (pH 7.4),
15 mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 mM spermi-
dine, 2 mM CaCl2). Chromatin was subjected to micrococcal
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nuclease (MNase) digestion, with varying concentrations of
MNase concentration, in MNase buffer at RT to yield nucleo-
somal fragments. The addition of 25 mM EDTA and 0.2% SDS
stopped the reactions. Cellular debris was pelleted and the
supernatant recovered. Lysates were diluted 1:10 in ChIP
dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
167 mM NaCl, protease inhibitors, 16.7 mM Tris–HCl, (pH 8).
Non-specific background was removed by incubating the
MNase digested chromatin with Protein A/G dynabeads
(Invitrogen, Carlsbad, CA, USA) overnight at 4 °C with rota-
tion in the presence of BSA (250 μg ml−1). Precleared chromatin
solutions were incubated overnight at 4 °C with rotation with
antibodies against PARP1 (#39559, Active Motif, Carlsbad,
CA, USA), H3 (ab1791, Abcam, Cambridge, MA, USA) and
for control, immunoglobulin G (I8140; Sigma-Aldrich,
St Louis, MO, USA). For quality control, 100 μl of the pre-
cleared chromatin was purified by QIAquick PCR Purification
Kit (Qiagen, Germantown, MD, USA) and DNA fragment
sizes were analyzed and confirmed to correspond to one to three
nucleosome fragments. For the ChIP samples, the complex was
washed and eluted, and immunoprecipitated material was
purified using the QIAquick PCR Purification Kit (Qiagen).
The purified DNA was analyzed by qPCR with respect to
input using GelStar (Lonza, Walkersville, MD, USA)) and Taq
DNA Polymerase (Invitrogen).
Quantitative real-time PCR was used to measure PARP1,
nucleosome and H3K4me3 occupancy. ChIP-qPCR experi-
ments were done with the following antibodies: PARP1, H3 and
H3K4me3 to measure for PARP1, nucleosome and H3K4me3
occupancy according to ref 72. PCR signals from immunopre-
cipitated samples were normalized to input and in some cases to
the total histone H3 control.
Nuc-ChIP-seq and MNase-seq data analyses
Nuc-ChIP-seq was performed following the protocol
described in our recent publication [28]. As no peak-calling
program has gained consensus acceptance by the scientific
community as the preferred tool for ChIP-Seq data analysis [73],
we used two different methods to analyze the sequenced reads.
Method 1 Nucleosomes were defined as described in [74, 75].
To define nuc-ChIP- seq and MNase-seq centers based on the
single-end reads we first estimated the average DNA insert
length, d. We calculated the cross-correlation of the tag start
positions between the reads on the Watson and Crick strands
and identified the peaks at d= 156 and d= 150 for the PARP1-
bound nucleosomes and total nucleosomes, respectively. Thus,
the tags on the Watson and Crick strands were shifted by d/2
toward 3′ and 5′, respectively, so that the tag frequency on
position i can reflect the probability of position i being the
PARP1-bound nucleosome or total nucleosome centers. The
relative abundance of PARP1-bound nucleosomes was esti-
mated by counting the number of PARP1-ChIP-seq nucleosome
centers within each region and dividing that by the total number
of mapped reads. Custom scripts were used to calculate the
nucleosome center as previously done [28, 74, 75].
Method 2 Model-based Analysis for ChIP-Seq (MACS) was
used to identify peaks from the nuc-ChIP-Seq data as follows.
For each replicate, a default P-value significance of 1× 10− 5 was
defined as significant. ChIP-Seq peaks were detected using
Macs2 [76, 77], with the broad option and a window size of
200 bp. Overlaps between each ChIP-Seq data peaks and
PARP1 peaks were determined by using an overlap of at
least 10% of the ChIP-Seq peak with the PARP1 peak. Both
methods yielded very similar results in spite of having different
limitations: method 1 produces background noise and method 2
possibly eliminates PARP1 binding sites. To visualize
PARP1-bound nucleosome tag-density across the human
chromosomes on the UCSC browser for hg19, ready-to-
visualize bedgraph files were created using the HOMER
package v3.13 [78]. In brief, aligned reads were extended to the
average fragment size (109–160 bp) and read coverage on each
base across the genome was calculated. Read coverage was then
scaled to one million and normalized with the total number of
reads. All publicly available data used for pairwise comparisons
with our PARP1 data were processed in the same way. We also
used total nucleosome (nucleosome-seq) data to normalize for
background correction.’
Native ChIP (NChIP) of SF3B1-bound nucleosomes
NChIP was performed similarly to nuc-ChIP described
above albeit with no fixation step. In this protocol, antibodies
used were SF3B1, PARP1 and H3 antibodies.
HeLa cell extract fractionation
HeLa cell extract fractionation was done according to
ref. 79. In brief, nuclear extract fromHeLa cells was loaded onto
a linear 4-ml 15–30% glycerol gradient prepared in G150 buffer
(20 mM HEPES, pH 7.9, 150 mM NaCl, 1.5 mM MgCl2, 0.5 mM
dithioerythritol). Gradient was centrifuged in a Beckman
SW60Ti rotor at 35 000 rpm, at 4 °C for 15 h. Thereafter, the
gradient was fractionated into 26 fractions of 150 μl each. In
total, 30 μl aliquots from the fractionated samples were loaded
onto 10% SDS–PAGE. To estimate the Svedberg (S) values, we
used conalbumin (molecular weight 75 000 D; 5.4S), aldolase
(15 800 D, 11.5S) and ferritin (440 000, 17S), all from GE
healthcare, Piscataway, NJ, USA.
siRNA production and treatment of cells
PCR product made against specific exons of PARP1
(siRNA1 for KD1) was obtained from the Lis laboratory -
Cornell University, Ithaca, NY, USA [29]. PCR products made
against the specific exons of PARP1 (siRNA2) and LacZ were
obtained from the Drosophila RNAi Screening Center (FlyR-
NAi.org – the database of the Drosophila RNAi screening
center: 2012 update) to produce double-stranded RNA
(dsRNA) for PARP1 knockdown and non-targeting control
LacZ. PCR products were further amplified and dsRNA was
produced and purified according to the manufacturer –
MEGAscript RNAi Kit (Life Technologies). RNAi treatments
were as follows: S2 cells were treated with dsRNA, produced
according to the Ambion MEGAscript manual. To achieve
efficient RNAi knockdown (430%), concentrations of ~ 10 nM
of dsRNA (siRNA) were used. siRNA targeting the coding
sequence of β-galactosidase (LacZ) was used as a non-specific
control. SiRNAs against human PARP1 (ON-TARGETplus)
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from Thermo Scientific Dharmacon and transfection was per-
formed as per the manufacturer using Dharmafect reagent 2.
Inhibition of PARP1 in D. melanogaster cells
PJ34 was added to S2 cells in media, at final concentrations of
300 nM and 10 μM and incubated further for 10 h at growth
temperature [29, 38]. Cells were harvested for total RNAs
extraction. Inhibition of PARylation was validated using
Trevigen’s Pharmacodynamic Assay II (4520-096-K) according
to manufacturer’s instructions.
Antibodies
The following antibodies were used in this study: CHIP-grade
PARP1 (Active Motif: 39559), CHIP-grade H3 antibody
(Abcam: ab1791), CHIP-grade H3K4me3 antibody (Abcam:
ab1791) and CHIP-grade custom-made SF3B1, which was a
kind gift from the Stamm laboratory, University of Kentucky,
Lexington, KY, USA.
PAR-CLIP
PAR-CLIP was performed according to ref. 49. Samples
were run on 8–20% PAGE gel (Invitrogen) and transferred
on nitrocellulose membrane before visualization on a phos-
phoimager. Segments representing PARP1-bound RNAs were
excised from membrane, purified and reverse transcribed into
complementary DNA (cDNA) using qScript cDNA Supermix
(Quanta Biosciences, Gaithersburg, MD USA).
Analyses of gene expression data
Drosophila genome TSSs, transcription stop ends, exon/
intron junction data and gene expression data were downloaded
from http://genome.ucsc.edu/cgi-bin/hgTables and http://inter
mine.modencode.org, respectively, and processed as below:
RNA-seq data analyses
A total of six fastq files were analyzed in this study, each
representing a separate sample (two control; two PARP1 KD,
and two PARylation). These fastq files were examined for
quality control using FastQC [80]. Examination of the results of
FastQC indicated that no further pre-processing was necessary.
The RNA-seq reads were then processed using the Tuxedo suite
[39]. The first step mapped reads to the Drosophila reference
genome (dm3) using TopHat2 v2.0.10 [81] with the multi-
processor option –p 5 and the remaining parameters as the
TopHat2 defaults, allowing at most two mismatches to the
reference. In this analysis, we compared Control with PARP1
KD and PARylation. Transcripts were assembled using
Cufflinks v2.1.1 [39]. Aligned reads were used as inputs into
Cuffdiff2 [39] to detect DEGs, transcripts and ASEs along
with their abundances, guided by the flyBase dm3 gtf track
downloaded from the UCSC Genome Browser (http://genome.
ucsc.edu). A min-alignment-count of seven reads was used as the
threshold of the minimum number of reads that map to
each transcript, and a P-value ⩽ 0.05 was used to determine
differentially expressed (DE) events. FPKM (Fragments Per
Kilobase perMillion mapped reads) correlation analysis showed
high correlation between the two control samples (Pearson
correlation of r= 0.85; P= 3.14× 10− 13), between the two
PARP1-knockdown samples (Pearson correlation of r= 0.985;
P= 5.29 × 10− 21) and between the two PARylation inhibition
samples (Pearson correlation of r= 0.980; P= 9.37 × 10− 33),
indicating a very good transcript expression correlation between
replica libraries.
ASEs using MATS MATS [41] was used to measure ASEs.
Results were generated for five events: SE, mutually exclusive
exons, alternative 3′ splice sites, alternative 5′ splice sites and
retained introns. The cutoff splicing default difference is 0.0001
for 0.01% difference. Thus, the valid cutoff used is 0⩽ cutoff
o1. Second, AS events whose gene expression levels differed
more than the given cutoff fold change between the two samples
were filtered out. Valid: fold change41.0. The default is
10000.0.
Alternative splicing analysis Using MISO Alternative event
annotations for D. melanogaster were downloaded from
the MISO annotations page [42]. First, alternative event
annotations were indexed using the index_gff module, which is
part of the MISO toolkit. We ran MISO to get isoform
expression estimates. In this step, Psi values were computed for
each sample. We then made pairwise comparisons between
samples to detect DE isoforms/events. In this step, Bayes factors
and delta Psi values were computed between the samples. The
last step was to filter DE events based on different criteria. Given
a MISO Bayes factor comparison file for two-isoform events,
events can be filtered based on their coverage or magnitude
of change. We filtered our events based on the following
parameters: (a) at least 1 inclusion read (–num-inc 1); (b) at least
1 exclusion read (–num-exc 1); (c) the sum of inclusion and
exclusion reads is at least 10 (–num-sum-incexc10); (d) the ΔΨ is
at least 0.20 (–delta-psi 0.20); (e) the Bayes factor is at least 10
(–bayes-factor 10).
Comparing RNA-seq PARP1/PARylation-mediated ASEs
and PARP1 binding from nuc-ChIP-seq
We used Bowtie version 1.0.1 to map the read sequences to
the Drosophila genome dm3. We then used MACS (version
1.4.2 to call peaks for each replicate (and combined) PARP1-
binding site. We counted the number of peaks corresponding to
each event, by determining the overlap between each peak file
(PARP1 binding) with each event file (ASE). To determine
whether there were PARP1-binding sites associated with the
significant ASEs generated by MATS, we computed the number
of peaks (per replicate and combined) that correspond to each
event for each comparison.
Liquid chromatography-electrospray ionization-tandem
mass spectrometry analysis
After PAR-CLIP, samples on the beads were subjected to
SDS loading buffer and PAGE electrophoresis as follows: one-
third of IP samples were used directly for mass spectrometry to
determine the protein complex associated with PARP1 RNA.
The other third was subjected to stringent RNase A digest and
the last third was subjected to stringent DNase1 digest. These
latter samples were also used for (MS/MS) mass spectrometry
analyses, followed by scanning with Mascot as previously
reported [82]. Peptide matches that pass the filter associated with
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the strict False Discovery Rate (with target setting of 0.01) are
assigned as high confidence. For MS/MS ion search, proteins
with two or more high confidence peptides were considered
unambiguous identifications without manual inspection.
Proteins identified with one high confidence peptide were
manually inspected and confirmed. To generate the list of
proteins, we filtered the peptides retrieved from the database,
leaving only those with individual Mascot scores above 23 and
eliminating any consistent matches with IgG control sample as a
background.
LC-MS/MS analysis was performed using an LTQ-Orbitrap
mass spectrometer (Thermo Fisher Scientific, Waltham, MA,
USA) coupled with an Eksigent Nanoflex cHiPLC system
(Eksigent, Dublin, CA, USA) through a nano-electrospray
ionization source. The peptide samples were separated with a
reversed phase cHiPLC column (75× 150 mm) at a flow rate of
300-nl/min. The mobile phase A was water with 0.1% (v/v)
formic acid, whereas B was acetonitrile with 0.1% (v/v) formic
acid. A 50-min gradient condition was applied: initial 3%mobile
phase B was increased linearly to 50% in 24 min and further to
85% and 95% for 5 min each before it was decreased to 3% and
re-equilibrated. The mass analysis method consisted of one
segment with eight scan events. The first scan event was an
Orbitrap MS scan (100–1600 m/z) with 60 000 resolution for
parent ions followed by data dependent MS/MS for fragmen-
tation of the seven most intense ions with collision-induced
dissociation method.
MS/MS protein identification
The LC-MS/MS data were submitted to a local mascot server
for MS/MS protein identification via Proteome Discoverer
(version 1.3, Thermo Fisher Scientific) against Homo sapiens
(human) protein sequences contained within the Swissprot
database. Typical parameters used in the Mascot MS/MS ion
search were: trypsin digest with maximum of two miscleavages,
cysteine carbamidomethylation, methionine oxidation, a max-
imum of 10 p.p.m. MS error tolerance and a maximum of
0.8 Da MS/MS error tolerance. A decoy database was built and
searched. Filter settings that determine false discovery rates
(FDR) are used to distribute the confidence indicators for the
peptide matches. Peptide matches that pass the filter associated
with the strict FDR (with target setting of 0.01) are assigned as
high confidence. For MS/MS ion search, proteins with two or
more high confidence peptides were considered unambiguous
identifications without manual inspection. Proteins identified
with one high confidence peptide were manually inspected and
confirmed.
Validation of isoform expression
Real-time quantitative reverse transcriptase-PCR analysis
Real-time PCR was performed in a total volume of 20 μl
including 2 μl of cDNA, primers (0.2 mM each) and 10 μl of
SYBR Green mix (Roche, Mannheim, Germany) using primer
sets (Supplementary Table S6). Reactions were run on a Biorad
CFX 96 machine using the following cycling parameters (95 °C
for 5 min, 35 cycles of 10 s at 95 °C, 20 s at 60 °C and 15 s at 72 °
C; melting curve: 10 s at 95 °C, 60 s at 60 °C). For quality-
control purposes, melting curves for all samples were acquired.
Transcripts levels were normalized to Actb and fold change was
quantified using the standard curve method. The relative
expression of each gene calculated as a fold difference between
treated and untreated samples. Experiments were conducted in
triplicate with at least three biological replicates.
Semi-quantitative PCR to measure isoform expression mRNA
expression analyses were performed as described [83]. In brief,
total RNAs were isolated (QIAGEN RNeasy) (Qiagen, Vinlo,
the Netherlands) from different experimental cells and digested
with DNase1 prior to reverse-transcription reaction with qScript
cDNA Supermix (Quanta Biosciences). Also total RNA from
0–12 h embryos from flies were isolated. The resultant cDNAs
were used in semi-quantitative PCR with the indicated primer
sets (Supplementary Table S6) and gels were stained with
GelStar (Lonza). PCR cycling parameters were 95 °C for 5 min,
23 cycles of 10 s at 95 °C, 20 s at 55 °C (depending on the
annealing temperature of the primers), and 15 s at 72 °C; 72 °C
for 5 min and 4 °C forever. PCR products were resolved on 2%
agarose gels and stained with GelStar Nucleic Acid Gel Stain.
Splice isoforms were confirmed by cloning the products from
PCR analyses using Topo blunt end cloning Kit (Invitrogen)
according to manufacturer’s protocol and sequenced using the
sanger method. At last, some of the detected transcripts are not
annotated and were confirmed by sanger sequencing. Products
from neighboring constitutive exons of the same genes were used
to standardize for total transcription.
In silico analysis
The following splice site prediction programs were used to
predict the effect of variants on the efficiency of splicing:
GeneSplicer (http://www.cbcb.umd.edu/software/GeneSplicer);
Splice Site Prediction by Neural Network (http://www.fruitfly.
org/seq_tools/splice.html); NNSPLICE 0.9 version (http://www.
fruitfly.org/seq_tools/splice.html); and Drosophila Melanogaster
ExonDatabase (http://proline.bic.nus.edu.sg/dedb/cgi-bin/viewer.
py?id= 13068). In silico PCR program, http://genome.ucsc.
edu/index.html?org=Human&db=hg18&hgsid= 142437216 was
used to first obtain the predicted amplicon sizes before experi-
mental PCR reactions were performed.
Western blots
Western blots were performed per standard protocol and
input dilutions were used as a quantitative indication of signal
linearity. In brief, protein samples were resuspended in a
reduced sample buffer 9 conatining SDS), and then electro-
phoresed on a Tris-glycine gel with Tris running buffer; blotted
to PVDF membrane; and sequentially probed with primary
antibodies against various proteins. Western blot-based detec-
tion was performed using alkaline phosphatase-coupled sec-
ondary antibodies with Vistra ECF for visualization, and images
were obtained using a Typhoon 9400. ImageQuant 5.2 software
was used to quantity of proteins in arbitrary units and relative
protein concentrations were standardized to β-actin levels.
Accession numbers
Data analyzed have been deposited in GEO with accession
numbers GSE56120 and GSE56073.
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